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Anticoagulant Therapy-Eastham of treatment and also later, when the patient is apparently adequately treated according to the prothrombin ratio. It appears that patients with venous lesions require more anticoagulant to produce the same partial thromboplastin clottingtime than do patients with arterial lesions, and this may have a bearing on relapses and further thromboses. Examination of results from 21 patients when they were bleeding suggests that the partial thromboplastin clotting-time may be a better test for the detection of potential bleeding and bruising after overtreatment, since it is sensitive to variations in concentration of factor IX, a factor which does not affect the prothrombin clottingtime. It is therefore proposed that the plasma partial thromboplastin clotting-time is the more valuable test for the control of oral anticoagulant treatment, and a suggested therapeutic range of values is given.
Disodium cromoglycate (FPL 670; Intal) is one of a series of chromone derivatives studied by Fisons Pharmaceuticals Limited. It has been shown to inhibit the effects of some specific types of reaginic antibody-antigen reactions. It is not an anti-inflammatory agent and it is not a bronchodilator, nor does it protect against the effect of histamine, of 5-hydroxytryptamine, or of slow-reacting substance (SRS-A).
The compound has been shown to be relatively non-toxic.
In acute toxicity tests in small laboratory animals the LD50 on parenteral administration was greater than 2,000 mg./kg. In prolonged tests no toxic effects were seen, except at doses greater than 30 mg./kg. Renal tubular degeneration was the only specific toxic effect noted at higher dosage. The compound is excreted rapidly in the bile and urine and there is no evidence in animals of accumulation in any tissue (Cox, 1967) . Experimentally in atopic volunteers there was a reduction of the bronchospasm induced by aerosol of the appropriate antigen when the compound was administered by inhalation previous to challenge. Only a small fraction (less than 10%) of the inhaled dose in man is absorbed, and it is rapidly excreted. When given by mouth less than 1% is absorbed, and its protective effect is probably insufficient to be of clinical value (Altounyan, 1968) .
A small double-blind crossover trial in adults showed significant clinical improvement in patients with allergic pulmonary disease (Howell and Altounyan, 1967) . On the basis of this and further clinical experience which has since been reported (Altounyan and Howell, 1968) these authors concluded that disodium cromoglycate is a major advance in the management of allergic airway disease. This view was supported by Kennedy (1967) but was not shared by Grant et al. (1967) . The present study was designed to evaluate the efficacy of this drug in the treatment of children suffering from asthma.
Method of Administration A plastic inhaler (Spinhaler) has been designed for the inhalation of the drug, which is dispensed as a micronized powder in gelatin capsules. The patient inhales the powder by taking a few deep breaths through the Spinhaler ; in practice this appliance has proved easy to use by co-operative children even with fairly severe asthma. It is easily cleaned and maintained, and incorporates a simple means of puncturing the capsules.
Plan of Trial
The object of the trial was to compare on a double-blind basis, using crossover technique, the condition of children with asthma, present throughout the year, during two periods of four weeks each.
The children inhaled the contents of four capsules a day (on rising, at lunch-time, at tea-time, and on retiring) during the whole trial. In one four-week period the capsules contained disodium cromoglycate, in the other a placebo. The order of treatment for each patient was allocated at random and was not known to anyone concerned in the trial until the final assessments were completed. During a two-week period before the trial the children had experience in the use of the Spinhaler when they were supplied with practice capsules ; initial biochemical and other observations were also made at this time.
The trial capsules were coloured pink, the practice capsules were colourless. The "active" capsules contained disodium cromoglycate 20 mg., isoprenaline sulphate 0.1 mg., and lactose 19.9 mg. The placebo capsules contained isoprenaline sulphate 0.1 mg., lactose 34.9 mg., and sodium sulphate (anhydrous) 5 mg. The practice capsules contained isoprenaline sulphate 0.1 mg. and lactose 39.9 mg.
The small dose of isoprenaline sulphate was included in the capsules to prevent bronchospasm, which may occur after the inhalation of a dry powder. Sodium sulphate was included in the placebo capsules to impart a slightly unpleasant taste similar to the " active " capsules. No other change was made in the routine treatment except when the clinical condition required an alteration in the dosage of antispasmodics or corticosteroids (see below).
Before inclusion of the children in the trial the nature of the project was carefully explained to them and their parents both verbally and in writing; the family doctors were also informed by letter.
Patients Included in Trial A total of 51 patients were admitted to the trial. Of these 41 were boys and 10 were girls. The average age was 10.8 years; the youngest was 5 and the eldest 16. They were all children with long-standing perennial asthma and most had been attending the clinic for a number of years. Seventeen of the 51 also had active flexural eczema.
No attempt was made to exclude children on long-term steroid treatment; indeed, as many as possible were included so as to embrace the more severe and persistent cases of asthma.
Twenty-two were on long-term steroid treatment before the trial started and the average duration of such treatment was two and a half years. The dose used varied from 15 to 2.5 mg. of prednisolone (or its equivalent) daily.
Methods of Assessment
Daily Records.-Each patient, with the help of a parent, was instructed how to keep a day and night record of asthma, cough, sputum, and all medicines taken; these were entered on to a printed card, the numerical scoring for symptoms shown on the back of the card ( Fig. 1) Patient's Preference.-On completion of the trial each patient was asked whether he or she would prefer to stop using the Spinhaler, to continue to use it with the capsules supplied in the first four-week period, or use it with those in the second four-week period.
Spirometry.-Each week throughout the trial the F.E.V.1 and F.V.C. were recorded both before and after inhalation of a 1% solution of isoprenaline sulphate for half a minute from a Bright-Smith nebulizer.
Requirements for Other Drugs. 
Further Analysis
Of the 51 cases originally admitted to the trial three were withdrawn within the first month because of failure to cooperate in taking the treatment regularly; the records of three further patients were incomplete. One other boy developed infective hepatitis before he had received disodium cromoglycate, and it was decided to withdraw him altogether. Thus 44 patients completed the trial satisfactorily, and the principal results from these children are given in Table I . The values shown in Table I 80 % of their predicted normal during the placebo period as well as in those whose F.E.V.1 was less than 80% of their predicted normal during either period. There was also a significant difference in the asthma score in favour of "'active" treatment in those patients recording asthma disability as well as in the use of inhalers. These results are summarized in Table II . In Fig. 3 the correlation between the opinion of the independent assessor and that of the patient, and the percentage change in F.E.V.1 are shown graphically. The patient's opinion of his overall chest symptoms was obtained from the questionary completed at the end of the "active" period and recorded on a five-point scale as follows: -2 much worse, -1 slightly worse, 0 about the same, + 1 slightly better, +2 much better. A similar method of scoring was used for the placebo period but the signs were reversed. The horizontal co-ordinate of each case was determined by the sum of the two scores. Points to the right of the origin are in favour of the drug, and vice versa. The results show a considerable degree of agreement between the opinions of the assessor, the patient, and the ventilatory tests, though it is apparent that in individual cases an improvement in F.E.V. values did not always correlate with the opinion of the patient or of the assessor, and vice versa. Similarly, the opinions of the assessor and of the patient were not always in agreement. been on steroids before the trial discontinued this treatment when disodium cromoglycate was introduced, but they did not 4 LI relapse sufficiently during the subsequent placebo period to require reintroduction of steroids. All three cases remained off steroid treatment during the three months of known treatment with disodium cromoglycate after the trial (see below).
Four patients (Cases 1, 19, 20, and 28) who were given placebo during the first period were maintained on a reduced steroid dose when they changed to disodium cromoglycate in the second period. Three patients (Cases 12, 15, and 16 ) who had reduced the dose of steroids during the initial four weeks while receiving disodium cromoglycate were maintained on a reduced dosage during the subsequent placebo period. In two of these the lower steroid dose was maintained for three months while receiving disodium cromoglycate, and in one case the steroid dose was reduced even further.
The steroid dosages in 18 cases at the end of the three months of known disodium cromoglycate therapy compared with those at the start of the trial show the following: steroids discontinued in five (Cases 1, 17, 28, 30, and 38) , reduced in six (Cases 2, 12, 15, 16, 20, and 21) , unchanged in six. In one patient (Case 42) who had not responded to disodium cromoglycate over a two-month period a small dose of prednisolone was substituted instead.
Bronchodilator Usage Twenty-three out of the 44 patients recorded in Table I used aerosol bronchodilators during the period of the trial. According to their records this was discontinued during the " active " treatment period in six cases, used less in 13 cases, and used more often in four cases. The number of doses inhaled was reduced from an average of 30 a patient during the placebo period to 13 during the active period (Table II) .
Further Studies
Of the 44 patients who completed the trial 42 were treated for a further three months with disodium cromoglycate on an open basis. Of these, 22 had shown, in the opinion of the independent assessor, initial improvement during the month of "active" treatment, and this was maintained on long-term treatment in 20 (91%) but not maintained in 2 (9%). There were 20 patients who had not shown improvement in the month on active treatment but on long-term treatment 6 (30%) did show improvement, though 14 (70%) did not.
While the trial period of one month did seem to give quite a good indication of the patients who might be improved on disodium cromoglycate it seems likely that a longer period of two or even three months would have given a better indication of which patients would benefit, and the effect may in some cases be manifest slowly. Two of the patients who failed to improve on long-term treatment developed soreness of the throat and stopped the treatment before completing the full three months.
Side-effects
Blood specimens were taken initially and at monthly intervals during the trial for haemoglobin, E.S.R., R.B.C., W.B.C., and differential white cell counts. Alkaline phosphatase, serum alanine aminotransferase, and serum aspartate aminotransferase were also measured. Urine specimens were examined weekly for sugar and protein. No abnormalities which could be ascribed to disodium cromoglycate occurred. One patient suffered from hoarseness and dryness of the mouth during the trial, which was quickly relieved when inhalation of the powder was stopped. This effect seemed to occur with both the active and the placebo powder. Two other patients complained of a similar effect during the three months of known treatment after the trial, recovering when it was stopped.
Conclusion
Our results with disodium cromoglycate in the treatment of children with asthma agree more with those of Howell and Altounyan (1967) and of Kennedy (1967) than with the less encouraging report of Grant et al. (1967) . The severity of asthma during the double-blind trial was assessed by several methods in which both objective and subjective criteria were used: all these methods suggested improvement on the drug. Some cases showed no detectable improvement on the drug; some of these non-responders were in a phase of remission so that their disability was minimal at the time of the trial. The opinion of the independent assessor was that in 24 (54%) of the 44 patients who completed the trial the patient was improved while on treatment. Twenty-five (57%) of them felt better on treatment. In 29 (66%) the F.E.V.1 was improved and in 30 (68%) the F.V.C. was improved compared with the readings in the placebo period.
Overall improvement seemed to be maintained in 20 out of 22 patients (91%) over a further three-month period of open treatment. Out of 20 patients who had not shown improvement after one month of treatment 6 (30%) did benefit after a further three months.
With its apparent freedom from serious side-effects, the reduction or successful replacement of steroid therapy in many cases may prove to be among the greatest benefits to be expected.
Summary
A double-blind crossover clinical trial of disodium cromoglycate (Intal) administration by inhalation for the treatment of asthma in 44 children has shown this preparation to have a beneficial effect. There were no ill effects except for occasional soreness of the throat and hoarseness. Some patients who had previously required continuous corticosteroid therapy were able to reduce the dose or to discontinue treatment without clinical deterioration. In most cases no loss of clinical benefit was observed over a three-month period of treatment. Much remains to be learned about the mode of action, the long-term effects, and the selection of suitable subjects for this novel method of treatment. Our results are encouraging and justify further study.
